Status and phase
Conditions
Treatments
About
PhI Dose Escalation with BOIN design in advanced Solid Tumor with Triple combination therapy to determine MTD and RP2D
Full description
Phase I dose escalation for triple combination therapy with BOINcomb design,The safety (including DLT), tolerability, and PK are the study endpoints of phase I and to determine MTD and RP2D.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
21 participants in 1 patient group
Loading...
Central trial contact
Vivien NA Deng; Lingmin NA Cong
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal